Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cue Biopharma Inc V.CUE


Primary Symbol: CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.


NDAQ:CUE - Post by User

Comment by nokiawatchon Jan 11, 2011 3:51pm
376 Views
Post# 17955795

RE: not the results

RE: not the results
  Its important to realize that the Uranium cycle is in early stage and that the Yuty property is so vast and unique, that this sector has a long way to reach its peak. Take this advice if you want. Buy all you can at this price  and hold. Nobody can say foresure where this will go, but there are good indications that show we will reach 2007 levels or beyond .IMHO I see this trading well above 1.00 and closer to  2.00 peak is a possibility. Its just a matter of time before CUE hits 1.00.  This should be trading much higher then its current level. The market is slow to realize the value here. The demand is there to increase and replenish supply. If oil reaches $140 or more this summer Uranium could be in for a run  at  $135/lb levels . I was hesitant at 1st to take  good profit from other commodities and buy into this after seeing years of  flat levels ,  but the time is now!  Yuty will be one of the top Uranium  deposit producers this world has to offer !
<< Previous
Bullboard Posts
Next >>